Dr Jinhui Xue speaks to ecancer about early clinical results for TQB2922, a novel bispecific antibody targeting both EGFR and c-MET, in patients with EGFR-mutant non-small cell lung cancer who progressed on third-generation EGFR tyrosine kinase inhibitors.

TQB2922 demonstrated promising antitumor activity as both monotherapy and in combination with bevacizumab and chemotherapy, with substantially higher response rates observed in the combination setting.

Progression-free survival outcomes also appeared encouraging, with many patients maintaining ongoing benefit at the time of analysis.

Dr Xue says that the treatment was generally well tolerated, with manageable safety profiles across both cohorts and no treatment-related discontinuations or deaths.

These findings support further development of TQB2922 as a potential strategy to overcome resistance in EGFR-mutant lung cancer.